Navigation Links
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Date:6/13/2013

p> Disease
Improvement /
Activity Measure24-WeekResponders/Total
Patients (Percent
Responders)52-WeekResponders/Total
Patients (Percent
Responders)ACR20

149/201 (74%)

139/196 (71%)ACR50

83/201 (41%)

96/197 (49%)ACR70

43/201 (21%)

53/197 (27%)CDAI Remission

34/200 (17%)

40/195 (21%)SDAI Remission

30/195 (15%)

42/194 (22%)DAS28 ESR <2.6

35/200 (18%)

47/195 (24%)DAS28 ESR </= 3.2

55/200 (28%)

82/195 (42%)DAS28 CRP <2.6

59/195 (30%)

80/194 (41%)DAS28 CRP </= 3.2

93/195 (48%)

116/194 (60%)Boolean Remission

19/195 (10%)

32/194 (16%) Safety ResultsSafety signals observed during the open-label extension were consistent with previously reported results of baricitinib. Among patients who remained on the 4 mg dose, treatment-emergent adverse events (TEAEs) occurred in 57 (53 percent); serious adverse events (SAEs) in 11 (10 percent); infections in 34 (31 percent); and serious infections in four (4 percent). Among patients who received the 8 mg dose, TEAEs occurred in 59 (63 percent); SAEs in eight (9 percent); infections in 37 (40 percent); and serious infections in two (2 percent). No opportunistic infections or tuberculosis cases were observed. There was one death in the 8 mg group due to a suspected myocardial infarction.

"In this clinical trial baricitinib showed statistically and clinically significant improvements in the features of this condition, which were maintained throughout a year of treatment. To date, baricitinib has demonstrated an acceptable safety profile and side effects have generally been straightforward to manage. These encouraging findings support further investigation of this new drug in rheumatoid arthritis," said Peter Taylor, M.A., Ph.D., F.R.C.P., Norman Collisson Chair of Musculoskele
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lilly to Present at Goldman Sachs Global Healthcare Conference
2. Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimers Disease Research and Development
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
5. Todays Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals
6. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
7. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
8. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
9. Neogen announces Bohannon retirement, successor named
10. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
11. Hemostemix Announces Formation of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... San Diego, California (PRWEB) January 22, 2015 ... R Promotional Offer to their comprehensive portfolio of ... Offer allows customers to purchase a Centrifuge 5424/5424 R ... Pipette Bundle of either Eppendorf Research plus or Eppendorf ...
(Date:1/22/2015)... Geneva, Switzerland (PRWEB) January 22, 2015 ... for characterized mammalian Research Cell Banks (RCBs) used for ... generated Research Cell Banks will include Next-Generation Sequencing ... cell’s genetic architecture de-risks biologic manufacturing by ensuring the ...
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... State spending on information technology may soon be subject ... costing tens of millions of dollars each, have failed ... and representative Suzanne Jeskewitz, co-chairs of the Joint Audit ... developed or renovated recently are inefficient or non-functional, and ...
... citywide wireless network in Milwaukee, the surrounding communities of ... , ,Waukesha and Wauwatosa are already being pitched by ... the city of Madison. Milwaukee's network is being built ... the deals established so far, the city is essentially ...
... At $2.5 million per 30-second spot, the average 2006 ... TV advertising has never been more affordable for small ... Spot Runner , it's possible to implement a comprehensive ... at a fraction of the normal cost. You can ...
Cached Biology Technology:Local TV advertising - Super Bowl vs. super bargain 2Local TV advertising - Super Bowl vs. super bargain 3Local TV advertising - Super Bowl vs. super bargain 4
(Date:12/11/2014)... blood pressure plays a role in human health has been ... for high blood pressure – was first described as a ... used in measuring blood pressure was invented in 1896. ... its triggers and its effects. In fact, recent findings have ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you ... remember your password, site key or the answer to your secret ... Today, Hoyos Labs , a digital infrastructure ... an end to the frustration that comes with usernames, passwords and ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... its School of Medicine. Funding for this $50 million capital ... be publicly launched next summer. The medical ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in Wake ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... , RENO, Nev. A novel treatment in development at ... common form of muscular dystrophy is advancing towards human trials ... The grant will be used to expand successful research by ... laminin-111 protein therapy prevents the onset of the devastating neuromuscular ...
... the strongest materials on Earth and are used to strengthen ... CNTs have potential uses in everything from medicine to electronics ... study by the University of Missouri and United States Geological ... The researchers urge that care be taken to prevent the ...
... AMES, Iowa Edward Yu took note of the facts ... each year, developments of multidrug-resistant, extensively drug-resistant and now totally ... to tuberculosis. Yu, an Iowa State University and Ames ... the three-part structure that allows E. coli bacteria ...
Cached Biology News:MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine 2MDA supports Duchenne muscular dystrophy research by University of Nevada School of Medicine 3Iowa State, Ames Lab researchers study the structure of drug resistance in tuberculosis 2Iowa State, Ames Lab researchers study the structure of drug resistance in tuberculosis 3
...
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
Biology Products: